Safety and Feasibility Study of Mesenchymal Trophic Factor (MTF) for Treatment of Osteoarthritis

Trial Profile

Safety and Feasibility Study of Mesenchymal Trophic Factor (MTF) for Treatment of Osteoarthritis

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 02 May 2017

At a glance

  • Drugs Mesenchymal stem cell therapy (Primary) ; Mesenchymal stem cell therapy (Primary)
  • Indications Osteoarthritis
  • Focus Adverse reactions
  • Sponsors Translational Biosciences
  • Most Recent Events

    • 26 Apr 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2019.
    • 26 Apr 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2018.
    • 26 Apr 2017 Status changed from active, no longer recruiting to withdrawn prior to enrolment.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top